Inventor · disambiguated record
Thomas Nittoli
Also filed as: NITTOLI THOMAS
36 granted patents·17 pending applications·300 citations·filing 2001–2025
97Inventor score
Top patents by PatentIndex Score
53 records- 0198US9950076B2Maytansinoid derivatives, conjugates thereof, and methods of useREGENERON PHARMA·Filed 2017·Granted Apr 24, 2018·34 cites·53 claims
- 0298US9302015B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Apr 5, 2016·82 cites·57 claims
- 0397US10772972B2Anti-STEAP2 antibody drug conjugates, and compositions and uses thereofREGENERON PHARMA·Filed 2017·Granted Sep 15, 2020·44 cites·41 claims
- 0496US10738130B2Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereofREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·50 cites·49 claims
- 0596US9951141B2Antibody-drug conjugates, their preparation and their therapeutic useREGENERON PHARMA·Filed 2015·Granted Apr 24, 2018·20 cites·54 claims
- 0695US11485793B2Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·4 cites·44 claims
- 0794US11633501B2Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Apr 25, 2023·3 cites·14 claims
- 0893US11142578B2Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereofREGENERON PHARMA·Filed 2017·Granted Oct 12, 2021·6 cites·26 claims
- 0993US10941208B2Anti-MUC16 antibodiesREGENERON PHARMA·Filed 2017·Granted Mar 9, 2021·6 cites·2 claims
- 1093US10463749B2Maytansinoid derivatives, conjugates thereof, and methods of useREGENERON PHARMA·Filed 2018·Granted Nov 5, 2019·4 cites·21 claims
- 1193US9475875B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Oct 25, 2016·14 cites·9 claims
- 1291US10738124B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Aug 11, 2020·3 cites·27 claims
- 1390US10570151B2Biologically active molecules, conjugates thereof, and therapeutic usesREGENERON PHARMA·Filed 2014·Granted Feb 25, 2020·12 cites·24 claims
- 1487US9545451B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·6 cites·21 claims
- 1584US11958910B2Bispecific antigen binding molecules that bind HER2, and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Apr 16, 2024·1 cites·22 claims
- 1684US9688764B2Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodiesREGENERON PHARMA·Filed 2016·Granted Jun 27, 2017·3 cites·47 claims
- 1783US11446389B2Maytansinoid derivatives, conjugates thereof, and methods of useREGENERON PHARMA·Filed 2019·Granted Sep 20, 2022·1 cites·19 claims
- 1882US10683354B2Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cellsREGENERON PHARMA·Filed 2018·Granted Jun 16, 2020·1 cites·26 claims
- 1982US10106616B2Antagonist antibodies to human prolactin receptor (PRLR)REGENERON PHARMA·Filed 2017·Granted Oct 23, 2018·2 cites·16 claims
- 2081US11377502B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Jul 5, 2022·1 cites·5 claims
- 2180US12378258B2Biologically active molecules, conjugates thereof, and therapeutic usesREGENERON PHARMA·Filed 2022·Granted Aug 5, 2025·0 cites·12 claims
- 2279US12419963B2Diels-Alder conjugation methodsREGENERON PHARMA·Filed 2023·Granted Sep 23, 2025·0 cites·16 claims
- 2378US2023116771A1Maytansinoid derivatives, conjugates thereof, and methods of useREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2477US12297207B2Maytansinoid derivatives, conjugates thereof, and methods of useREGENERON PHARMA·Filed 2021·Granted May 13, 2025·0 cites·8 claims
- 2576US2025223299A1Maytansinoid derivatives, conjugates thereof, and methods of useREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2676US2025250342A2Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2776US2023321109A1Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic usesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2875US10047160B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Aug 14, 2018·1 cites·13 claims
- 2974US2024190973A1Anti-fgfr2 antibodies and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3072US11866502B2Anti-FGFR2 antibodies and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Jan 9, 2024·0 cites·65 claims
- 3172US11608380B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Mar 21, 2023·0 cites·11 claims
- 3271US11345715B2Biologically active molecules, conjugates thereof, and therapeutic usesREGENERON PHARMA·Filed 2020·Granted May 31, 2022·0 cites·8 claims
- 3370US11596635B2Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic usesREGENERON PHARMA·Filed 2018·Granted Mar 7, 2023·0 cites·12 claims
- 3468US12497460B2Anti-MSR1 antibodies and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Dec 16, 2025·0 cites·30 claims
- 3567US11701427B2Diels-alder conjugation methodsREGENEREN PHARMACEUTICALS INC·Filed 2021·Granted Jul 18, 2023·0 cites·56 claims
- 3665US11752214B2Protein-antiviral compound conjugatesREGENERON PHARMA·Filed 2021·Granted Sep 12, 2023·0 cites·19 claims
- 3765US2024101672A1Anti-ptcra antibody-drug conjugates and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3864US2020385402A1Maytansinoid Derivatives, Conjugates Thereof, and Methods of UseREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 3963US2023277682A1Verrucarin a derivatives and antibody drug conjugates thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4062US6455570B1Polypyrrolinone based inhibitors of matrix metalloproteasesUNIV PENNSYLVANIA·Filed 2001·Granted Sep 24, 2002·2 cites·9 claims
- 4162US2025041433A1Protein-antiviral compound conjugatesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 4260US2024293566A1ANTI-EGFRvIII ANTIBODY DRUG CONJUGATES AND USES THEREOFREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 4358US11814428B2Anti-PTCRA antibody-drug conjugates and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 14, 2023·0 cites·22 claims
- 4458US2022143194A1Selenium antibody conjugatesREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4558US2016354482A1Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic usesREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 4656US10752690B2Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic usesREGENERON PHARMA·Filed 2018·Granted Aug 25, 2020·0 cites·20 claims
- 4755US2024189319A1Rifamycin analogs in combination with vancomycin and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 4854US2016375147A1Maytansinoid derivatives, conjugates thereof, and methods of useREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 4953US2023285581A1Rifamycin analogs and antibody-drug conjugates thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 5049US2008293712A1Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use ThereofWYETH CORP·Filed 2008·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Thomas Nittoli files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →